

Watchman LAA Occluder: Screening Sheet

Watchman Indication

The WATCHMAN Device is indicated to reduce the risk of thromboembolism from the left atrial appendage in patients
 :: with non-valvular AF who are at increased risk for stroke and systemic embolism based on CHADS₂ or CHA₂DS₂-VASc scores;
 :: are deemed by their physicians to be suitable for warfarin;
 :: and have an appropriate rationale to seek a non-pharmacologic alternative to warfarin

					Exclusion Criteria	
					Parameter	Value
LAA Size		0°	45°	90°	135°	
Ostium Diameter**	mm	mm	mm	mm	Largest LAA Diameter	< 16.8 mm or > 30.4 mm
Depth of Primary Lobe	mm	mm	mm	mm	Largest LAA Depth	< Largest LAA diameter
<i>Note: Diameter measurement tips</i>						
<i>At 0, measure from LCA to 2 cm from tip of coumadin ridge</i>						
<i>At other angles from top of MV annulus to 2 cm from tip of coumadin ridge</i>						
LAA Lobes						
Number of lobes	1	> 1				
LAA ostium to 2° lobe distance		≤ 1 cm	> 1 cm		Distance to 2° lobe	≤ 1 cm
Intracardiac Thrombus						
	Absent	Present			Intracardiac thrombus	Present
LAA Smoke						
	Absent	Mild	Moderate	Dense	Smoke	Dense
Atrial Septal Aneurysm						
Maximum Excursion		mm			Aneurysm excursion	> 15 mm
Maximum Length		mm			Aneurysm length	≥ 15 mm
Atrial Shunt						
	None	Small	Moderate	Large	Shunt Size	Large
Aortic Plaque						
	None	Nonmobile plaque	Mobile plaque ≤ 4 mm	Mobile plaque > 4 mm	Mobile Plaque	> 4 mm
Pericardial Effusion						
	None	< 2 mm	≥ 2 mm		Effusion Thickness	≥ 2 mm
Mitral stenosis						
		MV < 1.5 cm ²	MV ≥ 1.5 cm ²		MV Area	< 1.5 cm ²

Watchman Diameter	Compressed Diameters	
	Minimum	Maximum
21	16.8	19.3
24	19.2	22.1
27	21.6	24.8
30	24.0	27.6
33	26.4	30.4

Medical Therapy Post Watchman Implantation

First 6 weeks	Warfarin or NOAC
From 6 weeks to 6 months	Dual antiplatelet therapy
Post 6 month	Aspirin for life